Hemostemix Inc HMTXF

Primary Symbol: V.HEM

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > HEM has piqued the interest of industry participants.

<< Previous

Bullboard Posts

Next >>

Post by khandaanita4444on Mar 20, 2023 3:17pm

227 Views

Post# 35349597

HEM has piqued the interest of industry participants.

HEM has garnered good investor attention in the industry with its re-pricing tactic on its unit offering. The shares jumped with a nice return rate and moved with an average volume of 303.37k. Investing makes sense when all things align perfectly.

<< Previous

Bullboard Posts

Next >>

Why invest?